À la une FierceBiotech 20 avr. 2026 Agenus focuses on survival data as 0% response rate triggers primary miss Agenus focuses on survival data as 0% response rate triggers primary miss Ouvrir Signaux connexes FierceBiotech 20 avr. 2026 Odyssey charts fresh voyage to public markets after abandoning IPO plans last year FierceBiotech 20 avr. 2026 AstraZeneca’s faith in IL-33 inhibitor continues to pay off with latest phase 3 COPD win FierceBiotech 20 avr. 2026 How WuXi AppTec’s Integrated Platform Is Helping Therapies Move Faster from Discovery to Patients